Nephrology Therapeutics
1. List of Afinitor drug patents
Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Dosage: TABLET;ORAL
AFINITOR family patents
14
Norway
14
Japan
12
European Union
10
United States
10
Israel
9
Lithuania
8
Spain
8
Russia
7
Hong Kong
7
China
7
Portugal
6
Denmark
6
Cyprus
6
Slovenia
5
Czech Republic
5
Poland
5
Slovakia
3
Canada
3
Korea, Republic of
3
Mexico
3
Luxembourg
2
United Kingdom
2
Taiwan
1
Brazil
1
New Zealand
1
Australia
1
South Africa
1
Hungary
2. List of Anjeso drug patents
Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Dosage: SOLUTION;INTRAVENOUS
ANJESO family patents
8
United States
2
Korea, Republic of
2
China
2
Japan
2
Australia
2
European Union
1
Canada
3. List of Avycaz drug patents
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
| New Patient Population (NPP) | Dec 20, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 2024-02-26
Market Authorisation Date: 25 February, 2015
Dosage: POWDER;INTRAVENOUS
AVYCAZ family patents
6
United States
2
Poland
2
Japan
2
ME
2
France
2
Australia
1
Spain
1
Austria
1
Hong Kong
1
Turkey
1
Denmark
1
AP
1
Czech Republic
1
Germany
1
China
1
Yugoslavia
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Estonia
1
Argentina
1
EA
1
OA
1
Norway
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Costa Rica
1
Ecuador
1
Algeria
1
Bulgaria
1
South Africa
1
Slovakia
1
Slovenia
1
Hungary
1
European Union
4. List of Cabometyx drug patents
Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of a...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(1 year, 3 months from now) | |
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(13 years from now) | |
| US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
| US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
| New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Dosage: TABLET;ORAL
CABOMETYX family patents
67
United States
22
Japan
14
Australia
13
European Union
12
Korea, Republic of
9
Taiwan
8
Spain
7
China
7
New Zealand
6
Hong Kong
6
Denmark
6
Canada
5
Poland
5
Croatia
5
Slovenia
4
EA
4
Portugal
3
Austria
3
Singapore
3
Argentina
3
Cyprus
3
Israel
3
Mexico
2
Brazil
2
South Africa
2
Hungary
1
RS
1
Russia
1
Morocco
1
San Marino
1
Netherlands
1
Lithuania
1
Luxembourg
5. List of Cerdelga drug patents
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who ...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888544 | GENZYME CORP | Methods for treating Gaucher disease |
Dec, 2038
(15 years from now) | |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
Market Authorisation Date: 19 August, 2014
Dosage: CAPSULE;ORAL
CERDELGA family patents
4
United States
1
Korea, Republic of
1
China
1
Russia
1
Israel
1
Canada
1
Brazil
1
Singapore
1
Colombia
1
Mexico
1
Japan
1
Australia
1
European Union
6. List of Defitelio drug patents
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 30, 2023 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
Market Authorisation Date: 30 March, 2016
Dosage: SOLUTION;INTRAVENOUS
DEFITELIO family patents
6
United States
4
Korea, Republic of
2
China
1
Italy
1
Spain
1
Russia
1
Hong Kong
1
Brazil
1
Israel
1
Canada
1
Singapore
1
India
1
Mexico
1
Japan
1
Australia
1
Denmark
1
European Union
7. List of Fosrenol drug patents
Treatment: Reduction of serum phosphate in patients with end stage renal disease
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 2 months from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 26 October, 2004
Dosage: TABLET, CHEWABLE;ORAL
FOSRENOL family patents
8
United States
5
Denmark
5
European Union
4
Spain
4
Poland
4
Cyprus
4
Portugal
4
Slovenia
3
Canada
3
EA
3
Japan
3
Australia
2
Austria
2
Germany
2
China
2
Brazil
2
Norway
2
Korea, Republic of
2
South Africa
2
Hungary
1
IB
1
Hong Kong
1
Iceland
1
Czech Republic
1
Singapore
1
Argentina
1
New Zealand
1
Peru
1
Israel
1
Taiwan
1
Mexico
1
Finland
8. List of Fotivda drug patents
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2024
(10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | NA |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-03-10
Market Authorisation Date: 10 March, 2021
Dosage: CAPSULE;ORAL
FOTIVDA family patents
7
United States
6
Japan
3
European Union
2
Austria
2
Germany
2
Brazil
2
Canada
2
Norway
2
Australia
1
Spain
1
Hong Kong
1
Denmark
1
Poland
1
China
1
Russia
1
EA
1
New Zealand
1
Korea, Republic of
1
Belgium
1
Chile
1
Israel
1
Taiwan
1
Mexico
1
Netherlands
1
South Africa
9. List of Gelnique drug patents
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449173 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Dosage: GEL;TRANSDERMAL
GELNIQUE family patents
5
United States
4
Mexico
2
Spain
2
Canada
2
Japan
2
European Union
1
Korea, Republic of
1
Germany
1
Russia
1
China
1
Brazil
1
South Africa
1
Australia
10. List of Gemtesa drug patents
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 2024-12-23
Market Authorisation Date: 23 December, 2020
Dosage: TABLET;ORAL
GEMTESA family patents
8
United States
3
Japan
3
Korea, Republic of
2
Dominican Republic
2
China
2
Costa Rica
1
Spain
1
Austria
1
Hong Kong
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Morocco
1
Argentina
1
EA
1
ME
1
Nicaragua
1
New Zealand
1
Honduras
1
Croatia
1
Cyprus
1
Peru
1
Chile
1
Israel
1
Portugal
1
El Salvador
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Colombia
1
Tunisia
1
Slovenia
1
European Union
11. List of Glyxambi drug patents
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
Market Authorisation Date: 30 January, 2015
Dosage: TABLET;ORAL
GLYXAMBI family patents
7
United States
3
Canada
3
European Union
2
China
2
Japan
2
Korea, Republic of
2
Mexico
1
Spain
1
Hong Kong
1
Philippines
1
Turkey
1
Denmark
1
RS
1
Poland
1
EA
1
New Zealand
1
Croatia
1
Cyprus
1
Israel
1
Chile
1
Portugal
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
12. List of Goprelto drug patents
Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucou...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 2021-12-14
Market Authorisation Date: 14 December, 2017
Dosage: SOLUTION;NASAL
13. List of Injectafer drug patents
Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
| US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(4 years from now) | |
| US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Strength (NS) | Apr 28, 2024 |
| New Patient Population (NPP) | Nov 19, 2024 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 25 July, 2013
Dosage: SOLUTION;INTRAVENOUS
INJECTAFER family patents
24
United States
6
European Union
5
Korea, Republic of
3
Spain
3
Hong Kong
3
Denmark
3
Canada
3
Cyprus
3
Portugal
2
Germany
2
China
2
Brazil
2
Norway
2
Japan
2
Jordan
2
Australia
2
Slovenia
1
Uruguay
1
Austria
1
Malaysia
1
Poland
1
Russia
1
Argentina
1
New Zealand
1
Peru
1
Israel
1
Taiwan
1
Mexico
1
South Africa
1
Lithuania
1
Saudi Arabia
1
Hungary
14. List of Inlyta drug patents
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advan...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(11 years from now) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(13 years from now) | |
Drugs and Companies using AXITINIB ingredient
Market Authorisation Date: 27 January, 2012
Dosage: TABLET;ORAL
INLYTA family patents
14
United States
5
Japan
4
European Union
2
Spain
2
Poland
2
China
2
Canada
2
Singapore
2
Korea, Republic of
2
Portugal
2
Taiwan
2
Mexico
2
Australia
2
Slovenia
2
Hungary
1
Hong Kong
1
Philippines
1
Malaysia
1
Turkey
1
Denmark
1
Russia
1
Brazil
1
EA
1
New Zealand
1
Cyprus
1
Israel
15. List of Invokamet drug patents
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 10 months from now) | |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2014
Dosage: TABLET;ORAL
INVOKAMET family patents
45
United States
14
Japan
11
European Union
10
China
9
Argentina
9
Taiwan
8
Canada
8
EA
8
Australia
8
South Africa
7
Ukraine
6
Spain
5
Norway
5
New Zealand
5
Korea, Republic of
5
Ecuador
4
Malaysia
4
Iceland
4
Yugoslavia
4
Brazil
4
Israel
4
Mexico
4
Costa Rica
3
Denmark
3
Poland
3
Croatia
3
Cyprus
3
Peru
3
Portugal
3
Slovenia
2
RS
2
Singapore
2
ME
2
Hungary
1
Uruguay
1
Panama
1
Hong Kong
1
Nicaragua
1
Honduras
1
Guatemala
1
Chile
1
El Salvador
1
Netherlands
1
Colombia
1
Lithuania
1
Luxembourg
16. List of Invokamet Xr drug patents
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 10 months from now) | |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Dosage: TABLET, EXTENDED RELEASE;ORAL
INVOKAMET XR family patents
45
United States
14
Japan
11
European Union
10
China
9
Argentina
9
Taiwan
8
Canada
8
EA
8
Australia
8
South Africa
7
Ukraine
6
Spain
5
Norway
5
New Zealand
5
Korea, Republic of
5
Ecuador
4
Malaysia
4
Iceland
4
Yugoslavia
4
Brazil
4
Israel
4
Mexico
4
Costa Rica
3
Denmark
3
Poland
3
Croatia
3
Cyprus
3
Peru
3
Portugal
3
Slovenia
2
RS
2
Singapore
2
ME
2
Hungary
1
Uruguay
1
Panama
1
Hong Kong
1
Nicaragua
1
Honduras
1
Guatemala
1
Chile
1
El Salvador
1
Netherlands
1
Colombia
1
Lithuania
1
Luxembourg
17. List of Invokana drug patents
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 ...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(7 years from now) | |
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 10 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
Market Authorisation Date: 29 March, 2013
Dosage: TABLET;ORAL
INVOKANA family patents
51
United States
16
Japan
12
China
12
European Union
11
Australia
10
Argentina
10
Taiwan
9
Canada
9
EA
8
Ukraine
8
South Africa
7
Spain
7
New Zealand
6
Korea, Republic of
6
Ecuador
5
Malaysia
5
Brazil
5
Norway
5
Israel
5
Mexico
5
Costa Rica
4
Iceland
4
Denmark
4
Poland
4
Yugoslavia
4
Singapore
4
Croatia
4
Cyprus
4
Peru
4
Portugal
4
Slovenia
3
RS
3
ME
3
Hungary
2
Uruguay
2
Hong Kong
2
Nicaragua
2
Guatemala
2
Chile
2
Colombia
2
Lithuania
1
Panama
1
Honduras
1
San Marino
1
El Salvador
1
Jordan
1
Netherlands
1
Luxembourg
18. List of Jardiance drug patents
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 18, 2024 |
| M (M) | Feb 24, 2025 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
Market Authorisation Date: 01 August, 2014
Dosage: TABLET;ORAL
JARDIANCE family patents
7
United States
3
Canada
3
European Union
2
China
2
Japan
2
Korea, Republic of
2
Mexico
1
Spain
1
Hong Kong
1
Philippines
1
Turkey
1
Denmark
1
RS
1
Poland
1
EA
1
New Zealand
1
Croatia
1
Cyprus
1
Israel
1
Chile
1
Portugal
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
19. List of Korsuva drug patents
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
| US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
| US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 2025-08-23
Market Authorisation Date: 23 August, 2021
Dosage: SOLUTION;INTRAVENOUS
KORSUVA family patents
32
United States
3
Canada
3
Japan
3
Korea, Republic of
2
Malaysia
2
Russia
2
China
2
New Zealand
2
Israel
2
Mexico
2
Australia
2
South Africa
2
European Union
1
Spain
1
Hong Kong
1
Denmark
1
Poland
1
Brazil
1
Cyprus
1
Portugal
1
Lithuania
1
Slovenia
1
Hungary
20. List of Monoferric drug patents
Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8815301 | PHARMACOSMOS AS | Stable iron oligosaccharide compound |
Aug, 2029
(6 years from now) | |
Drugs and Companies using FERRIC DERISOMALTOSE ingredient
Market Authorisation Date: 16 January, 2020
Dosage: SOLUTION;INTRAVENOUS
MONOFERRIC family patents
8
United States
3
Denmark
3
China
3
European Union
2
Spain
2
RS
2
Poland
2
Croatia
2
Portugal
2
Lithuania
2
Slovenia
2
Hungary
1
Hong Kong
1
Philippines
1
Brazil
1
Canada
1
Ukraine
1
EA
1
Japan
1
New Zealand
1
Korea, Republic of
1
Cyprus
1
Mexico
1
Australia
1
South Africa
21. List of Myrbetriq drug patents
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for th...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(5 months from now) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(5 months from now) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(5 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Mar 25, 2024 |
| Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 28 June, 2012
Dosage: TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ family patents
12
United States
9
Japan
4
European Union
3
Spain
3
Denmark
3
Poland
3
China
3
Canada
3
Portugal
3
Slovenia
2
Russia
2
Brazil
2
Norway
2
Croatia
2
Korea, Republic of
2
Cyprus
2
Israel
2
Mexico
2
Australia
2
South Africa
2
Hungary
1
Austria
1
Hong Kong
1
Germany
1
New Zealand
1
Taiwan
1
Netherlands
1
Lithuania
1
Luxembourg
22. List of Nexavar drug patents
Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; Treatment of unresec...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(3 months ago) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(5 years from now) | |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Dosage: TABLET;ORAL
NEXAVAR family patents
12
United States
7
European Union
5
Japan
5
Korea, Republic of
4
Peru
3
Spain
3
Hong Kong
3
Denmark
3
China
3
Canada
3
Cyprus
3
Portugal
3
Australia
3
Slovenia
2
Malaysia
2
Poland
2
Brazil
2
Ukraine
2
Singapore
2
Morocco
2
Argentina
2
Norway
2
New Zealand
2
Croatia
2
Honduras
2
Guatemala
2
Israel
2
Taiwan
2
Mexico
2
Cuba
2
South Africa
1
Uruguay
1
Austria
1
Dominican Republic
1
Germany
1
Russia
1
Costa Rica
1
Ecuador
1
Tunisia
23. List of Normocarb Hf 25 drug patents
Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7300674 | DIALYSIS SUPS | Sterile low bicarbonate dialysis concentrate solutions |
Mar, 2023
(2 months ago) | |
Drugs and Companies using MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient
Market Authorisation Date: 26 July, 2006
Dosage: SOLUTION;INJECTION
NORMOCARB HF 25 family patents
3
United States
2
Canada
1
Australia
1
European Union
24. List of Omontys drug patents
Treatment: Treatment of anemia due to chronic kidney disease
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
Market Authorisation Date: 27 March, 2012
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS family patents
21
United States
6
Japan
3
Korea, Republic of
3
European Union
2
China
2
Brazil
2
Canada
2
Ukraine
2
Singapore
2
EA
2
Norway
2
New Zealand
2
Mexico
2
Australia
2
Costa Rica
2
South Africa
1
Spain
1
Hong Kong
1
Austria
1
Iceland
1
Denmark
1
AP
1
Poland
1
Germany
1
Yugoslavia
1
Morocco
1
OA
1
ME
1
Croatia
1
Cyprus
1
Israel
1
Portugal
1
Georgia
1
Slovenia
25. List of Opana Er drug patents
Treatment: Dose modification for renal impairment
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(4 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Dosage: TABLET, EXTENDED RELEASE;ORAL
OPANA ER family patents
5
United States
26. List of Rayaldee drug patents
Treatment: Treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversup...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE family patents
11
United States
6
Korea, Republic of
5
European Union
4
Hong Kong
4
Japan
3
Spain
3
Portugal
3
Denmark
2
Poland
2
China
2
Cyprus
2
Canada
2
Slovenia
1
Norway
27. List of Recarbrio drug patents
Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 2028-07-16
Market Authorisation Date: 16 July, 2019
Dosage: POWDER;INTRAVENOUS
RECARBRIO family patents
4
United States
3
Japan
3
Lithuania
2
Spain
2
Hong Kong
2
Denmark
2
RS
2
Poland
2
China
2
Croatia
2
Korea, Republic of
2
Cyprus
2
Portugal
2
Ecuador
2
Netherlands
2
Slovenia
2
Hungary
2
European Union
1
Dominican Republic
1
Malaysia
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Norway
1
ME
1
Nicaragua
1
Honduras
1
New Zealand
1
Israel
1
Mexico
1
Australia
1
Costa Rica
1
South Africa
1
Colombia
1
Luxembourg
28. List of Recorlev drug patents
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage...
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) | |
| US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Dosage: TABLET;ORAL
RECORLEV family patents
5
United States